Latigo Biotherapeutics Inc.
NASDAQ:LTGOMedical - Pharmaceuticals
+$0.76 today
- Market cap
- $800.64M
- Beta
- 0.00
Volume 0.21M
Average 0.38M
Returns on capital
Latigo Biotherapeutics Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
No return metrics data available.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Todd N. Smith | PresIdent, CEO & Director | USD 1.06M | 56 | 105.54K | 0.16% |
Nima Farzan | Executive Officer | USD 1.06M | 50 | 114.45K | 0.17% |
Neil Kumar Singla | Chief Medical Officer | USD 1.01M | 54 | — | — |
Neha Krishnamohan | Chief Business Officer & CFO | USD 37.5K | 39 | 9.90K | 0.01% |
Bryan Moyer | Senior Vice President of Discovery | — | — | — | — |
Caroline Dougherty | Vice President of Corporate Development | — | — | — | — |
Julia Chapman | Senior Vice President of Operations | — | — | — | — |
Polina German | Senior Vice President of Clinical Pharmacology & Translational | — | — | — | — |
Sabrina Nieder | VP & Corporate Controller | — | — | — | — |
Vicki Holloway | Secretary | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 18, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 6, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$5.04M
Sells
0
$0.00
Net Transaction Value
+$5.04M
Net buying
Most Active
Foresite Capital Management V, LLC
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 10, 26Aug 10, 2026 | Foresite Capital Management V, LLC Indirect | Buy | $2.5M$2,520,000.00 |
| Aug 10, 26Aug 10, 2026 | Tananbaum James B. Indirect | Buy | $2.5M$2,520,000.00 |
Summary
Insiders reported 2 buys worth $5.04M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $5.04M. Foresite Capital Management V, LLC was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
Competitors
Who does Latigo Biotherapeutics Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about LTGO's management, answered from reported figures.
Who manages LTGO?
Latigo Biotherapeutics Inc. (LTGO) lists 10 active executives. The top listed executive is Todd N. Smith, PresIdent, CEO & Director.
Are LTGO insiders buying or selling?
Recent insider activity shows net buying of $6.94M.
Continue the stock analysis
Jump to another research area for this company.